10-methyl-acridinium; nitrate | 5911-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 10-methyl-acridinium; nitrate
• 英文别名: 10-Methyl-acridinium; Nitrat；10-Methylacridin-10-ium nitrate；10-methylacridin-10-ium;nitrate
• CAS: 5911-74-0
• 化学式: C₁₄H₁₂N*NO₃
• 分子量: 256.261
• InChiKey: POOOPOCMBCGKAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.58
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9,10-dihydro-10-methylacridine 在 硝酸 作用下， 生成 10-methyl-acridinium; nitrate
  参考文献：
  名称：

  Decker; Dunant, Chemische Berichte, 1906, vol. 39, p. 2721

  摘要：

  DOI：

文献信息

• Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2
  申请人：Pfizer Products Inc.

  公开号：EP1170594A2

  公开（公告）日：2002-01-09

  The present invention relates to the discovery that PGD2 is the natural ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD2-related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.

  本发明涉及发现 PGD2 是孤儿受体 CRTH2 的天然配体，现在人们马上就会认识到，这种相互作用对于开发有价值的药物非常重要。因此，本发明涉及用于治疗 PGD2 相关疾病（如过敏、哮喘和炎症）的治疗化合物的筛选方法。本发明还公开了适当的检测方法。
• Methods for the identification of compounds useful for the treatment of disease states medicated by prostaglandin D2
  申请人：——

  公开号：US20020022218A1

  公开（公告）日：2002-02-21

  The present invention relates to the discovery that PDG 2 is the nautral ligand for orphan receptor CRTH2, which interaction, it will now immediately be recognized, is important in the development of valuable pharmaceuticals. The present invention is therefore related to methods for screening for therapeutic compounds useful in the treatment of PGD 2 -related disorders such as allergy, asthma and inflammation. Appropriate assay methodology is also disclosed.

  本发明涉及发现 PDG 2 是孤儿受体 CRTH2 的中性配体，这种相互作用对于开发有价值的药物非常重要。因此，本发明涉及用于治疗 PGD 2 -相关疾病（如过敏、哮喘和炎症）的治疗化合物的筛选方法。本发明还公开了适当的检测方法。
• A PROCESS OF QUANTIFYING CELL NUMBER
  申请人：Packard Instrument Company, Inc.

  公开号：EP0660876A1

  公开（公告）日：1995-07-05
• PROCESS FOR PREPARING POLYVINYLBUTYRAL SHEET
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0815166A1

  公开（公告）日：1998-01-07
• EP0815166A4
  申请人：——

  公开号：EP0815166A4

  公开（公告）日：1998-06-10